Global Healthy Living Foundation’s Director of State and National Advocacy, Stephen Marmaras, recently was interviewed on the radio in Alaska to discuss recent biosimilar legislation and its implications for Alaskans.
The best-selling drugs Humira and Enbrel have a lot in common. They both use biotechnology to treat rheumatoid arthritis, psoriasis and other autoimmune diseases. And they come with giant price tags approaching $50,000 a year.
The overall aim of biosimilar is to help contribute toward the reduction of cost for patients.
Imagine you’ve been living with rheumatoid arthritis for more than ten years.
The existence of CT-P13, a biosimilar version of infliximab (Remsima), and its recommended approval on Tuesday by the FDA Arthritis Advisory Committee, is reason to celebrate.
Director, State and National Advocacy Stephen Marmaras speaks with David Lile on Columbia Morning on House Bill 1366
Patient advocacy groups are praising the FDA for releasing a draft guidance that outlines the FDA’s proposed guidelines for naming biologics and biosimilars.
Oftentimes, we forget how valuable our FDA is because we are used to only seeing the sensational critiques in the media: unwarranted drug approvals, inadequate surveillance, negligent public alerts or inappropriate industry influence.
If you ask patients with severe chronic diseases, such as those with rheumatoid arthritis, cancer, or multiple sclerosis, what they believe is the most important factor in achieving a positive outcome for their condition or disease, the vast majority will say it’s the relationship they have with their physician and treatment team.
Rheumatoid arthritis patient advocates for continued access to medication in North Dakota
The bond between patients and healthcare providers has always been based on trust and transparency
The FDA’s approval of Zarxio, the first biosimilar product authorized for use in the United States, led to a flurry of predictions Friday about billions of dollars in savings and expanded access to treatment for patients. But what exactly are biosimilars, and why are they being hailed in this way?
Very recently during the 64th Legislature in the State of Washington, House Bill 1675 was introduced relating to the prescription of biological products and interchangeable biological products.
The U.S. Food and Drug Administration (FDA) approved the first biosimilar in early March. Three others are undergoing the agency’s review, which is just the tip of the iceberg…
Steve Marmaras on AM Baton Rouge discussing about biosimilar legislation.
We can all likely agree we’re lucky drugs aren’t recalled as frequently as cars.
For patients with chronic diseases, medication can be very costly and there’s no guarantee it’ll work.
Would you want your pharmacist to tell you and your doctor if they substituted your biologic medication with a similar, but not identical drug? Of course you would. But as biosimilars — a less expensive mimic of Biologics — are introduced on the U.S. market, individual states are deciding how and when they can be […]
Watch the Video
Without the medicine Rachelle Crow takes for her rheumatoid arthritis, the 29-year-old Michigan woman’s face would frequently feel as if it were engulfed in flames. She would barely be able to crawl out of bed. She would have trouble opening or closing her fists or lifting her 3-year-old daughter. Crow can do all those things […]
Julie Wiles of Spring says she found relief from rheumatoid arthritis when she began receiving injections of Enbrel, a drug that costs $2,500 a week. But even with insurance coverage, Wiles can no longer afford Enbrel. Instead, she takes a combination of less expensive drugs and injections that hasn’t been nearly as effective. Read […]
Novartis still has to win a patent-infringement lawsuit before it can sell Zarxio, the first biosimilar to receive FDA approval, but experts and advocates indicate the potential rollout of the drug is less important than the fact that the approval has smoothed the way for the four biosimilar applications in front of the FDA. Read […]
Last year, when Mariah Leach was pregnant with her son, her rheumatoid arthritis flared up again. She had stopped medication during pregnancy, but when the autoimmune disease, which causes painful and damaging inflammation in joints and elsewhere, resurged, she and her doctors made the difficult decision for her to restart during her third trimester, based […]
The positive impact of biologic medicines for the treatment of many chronic diseases, such as multiple sclerosis, HIV, hepatitis C, Rheumatoid arthritis and others, cannot be understated. That’s why it’s good news that soon patients and prescribers will have access to cutting edge medicines called biosimilars. Read More
In a move expected to increase competition and lower drug prices, the Food and Drug Administration today approved the first “biosimilar” drug, designed to closely mimic existing drugs grown in living cells. Pharmaceutical companies have been able to produce low-cost generic drugs for three decades, but they haven’t before been able to produce knockoff versions […]
Clearly, there is a real need to ensure the safe and warranted use of prescription pain medications. Yet while regulators debate access restrictions, a part of the conversation that remains unheard is what access limitations mean for patients very much in need of appropriately prescribed medications.